• 2024
  • 2023
  • 2022
  • 2021
  • 2020

R&D Pipeline

R&D Pipeline (In-House)

As of January 2024

Generic Name
/ Development Code
Expected Indications Category Development Stage Development Classification
CG0070 Non-muscle-invasive bladder cancer Oncolytic Viral Therapy Phase III In-licensed /
CG Oncology (U.S.)

Linzagolix
/ KLH-2109

Uterine fibroids GnRH receptor antagonist Phase III Kissei
Endometriosis Phase II Kissei
KDT-3594 Parkinson's disease Dopamine receptor agonist Phase II Kissei
KSP-0243 Ulcerative colitis Phase II Kissei


Rovatirelin (spinocerebellar degeneration): Withdrew the application (July 2023) and considering the possibility of conducting additional clinical trials



R&D Pipeline (Out-Licensing)

As of January 2024

Generic Name
/ Development Code
Expected Indications Category Countries & Regions Development Company Development Stage
Linzagolix Uterine fibroids GnRH receptor antagonist EU Theramex (U.K.) Approved
China Bio Genuine (China) Phase III
Taiwan Synmosa Biopharma (Taiwan) NDA preparation
Endometriosis EU Theramex (U.K.) Phase III
China Bio Genuine (China) Phase III
Silodosin Dysuria associated with benign prostatic hyperplasia Alpha 1A adrenergic receptor antagonist Vietnam, etc. Eisai (Japan) NDA
Fostamatinib Chronic idiopathic thrombocytopenic purpura Tyrosine kinase inhibitor Korea JW Pharmaceutical (Korea) NDA
KDT-3594 Parkinson's disease Dopamine receptor agonist China, etc. AffaMed Therapeutics (China) Phase II